(P1) Altimmune is advancing its GLP-1/glucagon dual agonist, pemvidutide, into a pivotal phase III study for metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, positioning it to compete in a multi-billion dollar market with limited treatment options. The company's "pipeline in a product" strategy also includes mid-stage trials for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), with key data readouts expected this year.
(P2) "The totality of data from our IMPACT trial, showing both MASH resolution and fibrosis improvement with the added benefit of weight loss, gives us great confidence as we advance pemvidutide into phase III," an Altimmune spokesperson said.
(P3) The upcoming global phase III PERFORMA study will evaluate pemvidutide in MASH patients with moderate-to-severe fibrosis, with 52-week data anticipated in 2029. This follows a phase IIb IMPACT study where pemvidutide demonstrated statistically significant MASH resolution without worsening of fibrosis at 24 weeks, sustained through 48 weeks. Beyond MASH, top-line data from the phase II RECLAIM study in AUD is expected in the third quarter of 2026.
(P4) With a multi-billion dollar commercial opportunity in MASH and additional upside from alcohol-related liver diseases, Altimmune's pemvidutide is a key asset to watch. While shares have declined 18.9% year-to-date, successful phase III execution and positive data from its other liver disease programs could significantly re-value the company, which competes in a space with other players like MetaVia and their GPR119 agonist.
Altimmune’s strategy centers on leveraging pemvidutide’s dual agonist mechanism across a spectrum of liver diseases. The candidate holds Fast Track designations for both MASH and AUD, along with a Breakthrough Therapy Designation for MASH, highlighting the significant unmet need.
The company is also advancing pemvidutide in the phase II RESTORE study for patients with ALD, with enrollment expected to be completed by the third quarter of 2026. This multi-pronged approach diversifies the potential applications of pemvidutide beyond the highly competitive MASH landscape.
Altimmune currently holds a Zacks Rank #2 (Buy), with analyst estimates for its 2026 loss per share narrowing from $1.00 to 69 cents over the past 30 days. The broader biotech market continues to see speculative interest in companies with promising data in historically difficult-to-treat diseases. While Altimmune focuses on its clinical development, other companies like Akari Therapeutics and NeOnc Technologies are also gaining attention for their novel oncology platforms, and HCW Biologics recently secured financing for its immunotherapy pipeline.
This article is for informational purposes only and does not constitute investment advice.
